Lilly, Vir Biotechnology, GSK Say First Patient Dosed In Expanded BLAZE-4 Trial - Quick Facts

(RTTNews) - Eli Lilly and Co. (LLY), Vir Biotechnology, Inc. (VIR) and GlaxoSmithKline plc (GSK, GSK.L) said Wednesday they are collaborating to evaluate a combination of two COVID-19 therapies in low-risk patients with mild to moderate COVID-19.

Lilly has expanded its ongoing BLAZE-4 trial to evaluate the administration of bamlanivimab (LY-CoV555) 700mg with VIR-7831 (also known as GSK4182136) 500mg. Both are neutralizing antibodies that bind to different epitopes of the SARS-CoV-2 spike protein. The collaboration marks the first time that monoclonal antibodies from separate companies will be brought together to explore potential outcomes.

The companies said that the first patient has been dosed in the expanded BLAZE-4 trial.

Bamlanivimab is a neutralizing antibody directed against the spike protein of SARS-CoV-2 designed to block viral attachment and entry into human cells, thus neutralizing the virus. Bamlanivimab is authorized for emergency use for the treatment of mild to moderate COVID-19 in patients who are at high risk for progressing to severe COVID-19 and/or hospitalization.

VIR-7831 is a dual-action monoclonal antibody that was selected for clinical development based on its potential to both block viral entry into healthy cells and clear infected cells, as well as its potential to provide a high barrier to resistance.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Март 2021    »